---
title: "Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305698162.md"
description: "Novo Nordisk presented Phase 3 CagriSema trial data at ObesityWeek 2026, showing significant weight loss across lower doses and improved quality of life. The company also reported real-world Wegovy studies indicating reduced 'food noise.' With an NDA filed in December 2025, Novo Nordisk expects an FDA decision for CagriSema in Q4 2026. Shares rose 0.73% to $41.94."
datetime: "2026-11-16T15:46:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305698162.md)
  - [en](https://longbridge.com/en/news/305698162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305698162.md)
generator: "portal-rs"
---

# Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision

**Novo Nordisk** (NYSE:NVO) presented trial and real-world data at ObesityWeek 2026 showing strong weight loss for investigational CagriSema and reduced food noise among Wegovy users.

 **Read Also: Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval** 

## CagriSema Delivers Weight Loss Across Lower Doses

On Saturday, Novo Nordisk unveiled primary Phase 3 REDEFINE 9 results in Washington, D.C., alongside simultaneous publication in *The Lancet Diabetes & Endocrinology*.

The trial tested CagriSema, a fixed-dose combination of cagrilintide and semaglutide, at doses below its 2.4 mg / 2.4 mg maximum.

Assuming full adherence, adults taking the 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg doses achieved 20.7% and 21.0% average weight loss at week 68, versus 2.0% for placebo. They also cut waist circumference by 17.2 cm and 17.5 cm, respectively, compared with 3.6 cm for placebo.

Under the treatment regimen estimand, those doses produced 19.4% and 18.6% weight loss versus 4.6% for placebo.

## Early Responders and Quality-of-Life Gains

On Sunday, the company shared two post hoc analyses from the Phase 3 REDEFINE 1 trial of CagriSema 2.4 mg / 2.4 mg. About 67.8% of treated participants lost at least 5% of their body weight by week 8 and reached 25.4% mean weight loss at week 68, versus 17.8% for delayed responders.

At week 68, 73.1% reported meaningful physical function gains and 69.0% reported psychosocial improvements, topping placebo rates of 49.1% and 42.1%.

Novo Nordisk filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg and expects a decision in the fourth quarter of 2026.

U.S. regulators have not approved CagriSema, and trials have not established its safety and efficacy.

## Wegovy Reduces Food Noise in Real-World Studies

Novo Nordisk also presented Saturday findings from the retrospective SIGNAL and OCTANE studies using de-identified Ro telehealth data and a seven-item questionnaire tracking intrusive food thoughts.

In SIGNAL, 26,213 adults initiating semaglutide injections cut food-noise scores from a 2.72 baseline by 0.42 points at one month and 0.72 points at six months.

In OCTANE, adults starting oral semaglutide lowered food-noise scores by roughly 25% over three months, while 86.4% reported at least one improvement, including better-fitting clothing (67.5%) and healthier eating (51.6%).

**NVO Price Action:** Novo Nordisk shares were up 0.73% at $41.94 at the time of publication Monday, according to Benzinga Pro data.

 **Read Also: Dan Ives Dismisses Jensen Huang's Nvidia Comeback Speculation, Floats Tim Cook and Rene Haas for Top Job: 'Gone for Good'** 

*Photo: Shutterstock*

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOC.US](https://longbridge.com/en/quote/NVOC.US.md)
- [NVOH.US](https://longbridge.com/en/quote/NVOH.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)

## Related News & Research

- [Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026](https://longbridge.com/en/news/305572978.md)
- [Novo reports positive Phase III REDEFINE 1 results for CagriSema](https://longbridge.com/en/news/305668918.md)
- [Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops](https://longbridge.com/en/news/305843862.md)
- [Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show](https://longbridge.com/en/news/305552465.md)
- [Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026](https://longbridge.com/en/news/305552505.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**